Arpi Hagopian
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Arpi Hagopian.
Biochimica et Biophysica Acta | 1976
Jesse J. Jackson; Arpi Hagopian; Dennis J. Carlo; Guadalupe A. Limjuco; E.H. Eylar
The AP1 protein, a unique aspermatogenic protein localized in the sperm acrosome, exists as a single polypeptide chain of 136 amino acids, as shown by a single band on gel electrophoresis in sodium dodecyl sulfate and the recovery of the expected 21 to 22 tryptic peptides on peptide mapping. The AP1 protein appears to exist in a compact, highly stable conformation, as shown by its resistance to trypsin hydrolysis. Its aspermatogenic acitivity is not affected by trypsin treatment, by heating at 99 degrees C for 1 h, by 8 M urea, or by acid conditions. After reduction and alkylation, however, the molecule appears to open up, since it becomes hydrolyzable by trypsin and migrates more slowly on gel electrophoresis at pH 2.7 and 8.6. After alkylation, the AP1 protein still migrates as a single band at pH 2.7. The AP1 protein shows microheterogeneity near its isolectric point at pH 8.6; each of five bands shows the same amino acid analysis. Aggregation was not observed following treatment with dimethylsuberimidate. The molecular weight of 15 000, obtained from gel electrophoresis consists of 136 amino acids with a relatively high content of proline, half cystine, glycine, histidine and tryptophan. No galactose, mannose, fucose, glucose, or hexosamines were found; the AP1 protein is thus not a glycoprotein.
Advances in Experimental Medicine and Biology | 1989
Peter J. Kniskern; Arpi Hagopian; Pamela Burke; Nancy R. Dunn; D. L. Montgomery; Loren D. Schultz; C. A. Schulman; C. E. Carty; R. Z. Maigetter; D. E. Wampler; E. D. Lehman; S. Yamazaki; D. J. Kubek; Emilio A. Emini; William J. Miller; W. M. Hurni; Ronald W. Ellis
In summary, we have shown that yeast is the preferred host for the expression of recombinant-derived hepatitis B vaccines, and that a yeast expression system which is productive, stable and scaleable can be developed for each of the three HBV envelope proteins. The versatility of regulated and integrated yeast expression systems in the production of foreign polypeptides with biomedical utility also has been highlighted. We also have shown that careful attention to the development of recombinant clones helps to optimize the entire production process leading to highly purified products which share many biochemical properties with the plasma-derived vaccine. Furthermore, immunization with PreS2 sequences is capable of protecting chimpanzees from HBV infection. The availability of PreS2 + S and PreS1 + PreS2 + S proteins expressed in yeast now provides the opportunity for establishing the relevance of such candidate vaccines in preventing human disease, thereby highlighting the utility of molecular biology in modern vaccine development.
Biochimica et Biophysica Acta | 1976
Arpi Hagopian; Guadalupe A. Limjuco; Jesse J. Jackson; Dennis J. Carlo; E.H. Eylar
Of four glycoproteins isolated from guinea pig testes, two were aspermatogenic (types I and IV) and two (types II and III) were inactive. The glycoproteins were rich in carbohydrate, varying from 41.5% to 49.5% carbohydrate by weight. Each glycoprotein had a unique amino acid composition, but in general low levels of tyrosine, tryptophan, and basic amino acids were found along with relatively high contents of serine, threonine, glutamic acid, and proline. Types I and IV glycoproteins were remarkably stable; their aspermatogenic activity was not affected by urea, trypsin, or heating at 100 degrees C in water or in 1 M HCl for 15 min. Carbohydrate analysis revealed little difference in the monosaccharide compositions of types I and IV glycoproteins, except that only the type I contained sialic acid. In contrast, types II and III glycoproteins lacked sialicacid and fucose and contained much less mannose. Both N-acetylglucosamine and N-acetylgalactosamine were present in all four glycoproteins, and they dominated in the types II and III. Fucose and at least 20-25% of the galactose appeared to occupy terminal positions in type IV glycoprotein as shown by their release after 15 min hydrolysis in 1 M HCl. All of the glycoproteins contained a relatively high percentage of galactose by weight, from 12.6 to 19.3%. The molecular weights of the glycoproteins were estimated by sodium dodecyl sulfate gel electrophoresis to be 47000, 105000 and 18000 respectively for the types I, II, and IV; type III glycoprotein showed two major bands, with molecular weights of 41500 and 22800. All the above molecular weight values are probably overestimated because of high carbohydrate content. The molecular weight of type IV glycoprotein was found to be 13000 by ultracentrifugation; a corrected value of 29000 was calculated for type I glycoprotein.
Archive | 1992
Stephen Marburg; Richard L. Tolman; Peter J. Kniskern; William J. Miller; Arpi Hagopian; Charlotte C. Ip; John P. Hennessey; Dennis J. Kubek; Pamela Burke
Gene | 1986
Peter J. Kniskem; Arpi Hagopian; Donna L. Montgomery; Pamela Burke; Nancy R. Dunn; Kathryn J. Hofmann; William J. Miller; Ronald W. Ellis
Archive | 1992
Peter J. Kniskern; Charlotte C. Ip; Arpi Hagopian; Jr. John P. Hennessey; William J. Miller; Dennis J. Kubek; Pamela Burke
Hepatology | 1988
Peter J. Kniskern; Arpi Hagopian; Pamela Burke; Nancy R. Dunn; Emilio A. Emini; William J. Miller; Shigeko Yamazaki; Ronald W. Ellis
Journal of Immunology | 1975
Arpi Hagopian; Jesse J. Jackson; Dennis J. Carlo; Guadalupe A. Limjuco; E.H. Eylar
Archive | 1987
Ronald W. Ellis; Arpi Hagopian; Peter J. Kniskern; Donna L. Montgomery
Archive | 1997
Peter J. Kniskern; William J. Miller; Arpi Hagopian; Charlotte C. Ip; John P. Hennessey; Dennis J. Kubek; Pamela Burke